- Iridex Reports First Quarter 2024 Financial Results
- Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
- Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
- Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
- Iridex Corporation Receives European Patent on MicroPulse Technology
- Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
- Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
- Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
- Iridex Reports Third Quarter 2023 Financial Results and Business Update
More ▼
Key statistics
On Friday, IRIDEX Corp (IRIX:NMQ) closed at 2.43, 85.44% above the 52 week low of 1.31 set on Aug 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.45 |
---|---|
High | 2.54 |
Low | 2.43 |
Bid | 2.45 |
Offer | 2.55 |
Previous close | 2.47 |
Average volume | 26.06k |
---|---|
Shares outstanding | 16.25m |
Free float | 12.11m |
P/E (TTM) | -- |
Market cap | 39.49m USD |
EPS (TTM) | -0.6759 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼